Central Line-associated Bloodstream Infection (CLABSI)CLABSINCT07746674
Central Line-Associated Bloodstream Infection QI Project
An observational study of Central Line-associated Bloodstream Infection (CLABSI), run by NYU Langone Health at 1 site in United States.
Trial summary
This study evaluates a daily electronic health record (EHR) alert designed to reduce unnecessary central venous catheter (CVC) use among hospitalized adults. The alert identifies patients with an active CVC and no documented indication, prompting the first-contact provider to document line necessity. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Central Line-associated Bloodstream Infection (CLABSI)
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2026to Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult inpatients with an active central venous catheter for at least 24 hours who meet alert eligibility criteria during the study period
Who may be able to join
- Not hospice patient class
- Active central line for at least 24 hours
Who cannot join
- No active central line
- Central line present for less than 24 hours
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Central Line-Associated Bloodstream Infection (CLABSI) Quality Improvement Project
This study evaluates a daily electronic health record (EHR) alert designed to reduce unnecessary central venous catheter (CVC) use among hospitalized adults. The alert identifies patients with an active CVC and no documented indication, prompting the first-contact provider to document line necessity. The study compares alert and a secure chat intervention to usual care, with the goal of reducing unnecessary line days and related CLABSI risk.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Usual Care | Adult inpatients meeting eligibility criteria. | |
| Secure Chat + Alert Cohort | Adult inpatients meeting eligibility criteria whose provider receives a daily EHR OPA alert and additional secure chat communication. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total number of central line days without a documented indication
Measured: Up to Month 3
Secondary outcomes (2)
Number of femoral central lines in place for more than 2 days
Measured: Up to Month 3
Number of non-tunneled hemodialysis catheters without an active hemodialysis or continuous renal replacement therapy order
Measured: Up to Month 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2026
- Study startSep 2026 (estimated)
- Primary completionSep 2026 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Central Line-associated Bloodstream Infection (CLABSI)Studies of the same condition, open and under way.
- More trials run by NYU Langone HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- NYU Langone Health
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Holly Krelle, Principal investigator, NYU Langone Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07746674
- Sponsor's protocol ID
- QI-CLABSI
- Acronym
- CLABSI
- Status last verified
- Jul 2026
- First submitted
- 31 Jul 2026
- Last updated
- 5 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be made available to other researchers at this time.
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Central Line-Associated Bloodstream Infection (CLABSI) Quality Improvement Project
- ClinicalTrials.gov ID
- NCT07746674
- Acronym / sponsor ID
- CLABSI / QI-CLABSI
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- NYU Langone HealthUniversity, hospital or other
- Study start
- Sep 2026 (estimated)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 5 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates a daily electronic health record (EHR) alert designed to reduce unnecessary central venous catheter (CVC) use among hospitalized adults. The alert identifies patients with an active CVC and no documented indication, prompting the first-contact provider to document line necessity. The study compares alert and a secure chat intervention to usual care, with the goal of reducing unnecessary line days and related CLABSI risk.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Usual Care | – | –Adult inpatients meeting eligibility criteria. |
| Secure Chat + Alert Cohort | – | –Adult inpatients meeting eligibility criteria whose provider receives a daily EHR OPA alert and additional secure chat communication. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult inpatients with an active central venous catheter for at least 24 hours who meet alert eligibility criteria during the study period
Key inclusion criteria (2 listed)
- Not hospice patient class
- Active central line for at least 24 hours
Key exclusion criteria (2 listed)
- No active central line
- Central line present for less than 24 hours
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Total number of central line days without a documented indication
Time frame: Up to Month 3
2 secondary outcomes
Number of femoral central lines in place for more than 2 days
Time frame: Up to Month 3
Number of non-tunneled hemodialysis catheters without an active hemodialysis or continuous renal replacement therapy order
Time frame: Up to Month 3
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be made available to other researchers at this time.
Related trials for Central Line-associated Bloodstream Infection (CLABSI)
RecruitingPhase 3
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
Central Line Associated Blood Stream Infections (CLABSI)
Not yet recruiting
Neonatal Catheter Lock for Infection Prevention
CLABSI - Central Line Associated Bloodstream Infection, CRBSI - Catheter Related Bloodstream Infection
Recruiting
Impact of Infusion Line Change Frequency on Infectious Complications Related to Central Venous Catheters in the ICU - A Randomized Controlled Trial
Intensive Care (ICU), Central Venous Catheter Related Infections
Not yet recruiting
Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial
Vascular Access Complication, Device Related Infection
Active, not recruitingObservational study
Impact of Disinfectant Caps on Nosocomial CLABSI
Central Line-associated Bloodstream Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Holly Krelle principal investigator
NYU Langone Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Central Line-associated Bloodstream Infection (CLABSI), run by NYU Langone Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sarah Tsuruo (914-815-4079, Sarah.Tsuruo@nyulangone.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total number of central line days without a documented indication (time frame: Up to Month 3). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.